Cargando…
Impact of Sequencing Targeted Therapies With High-dose Interleukin-2 Immunotherapy: An Analysis of Outcome and Survival of Patients With Metastatic Renal Cell Carcinoma From an On-going Observational IL-2 Clinical Trial: PROCLAIM(SM)
Proleukin(R) Observational Study to Evaluate the Treatment Patterns and Clinical Response in Malignancy (PROCLAIM(SM)) is the largest observational clinical database of high-dose interleukin-2 (HD IL-2)-treated patients in the US. Herein, the survival and outcome for patients with renal cell carcino...
Autores principales: | Clark, Joseph I., Wong, Michael K.K., Kaufman, Howard L., Daniels, Gregory A., Morse, Michael A., McDermott, David F., Agarwala, Sanjiv S., Lewis, Lionel D., Stewart, John H., Vaishampayan, Ulka, Curti, Brendan, Gonzalez, René, Lutzky, Jose, Rudraptna, Venkatesh, Cranmer, Lee D., Jeter, Joanne M., Hauke, Ralph J., Miletello, Gerald, Milhem, Mohammed M., Amin, Asim, Richart, John M., Fishman, Mayer, Hallmeyer, Sigrun, Patel, Sapna P., Van Veldhuizen, Peter, Agarwal, Neeraj, Taback, Bret, Treisman, Jonathan S., Ernstoff, Marc S., Perritt, Jessica C., Hua, Hong, Rao, Tharak B., Dutcher, Janice P., Aung, Sandra |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6875755/ https://www.ncbi.nlm.nih.gov/pubmed/27916626 http://dx.doi.org/10.1016/j.clgc.2016.10.008 |
Ejemplares similares
-
A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanoma
por: Buchbinder, Elizabeth I., et al.
Publicado: (2016) -
Overall survival by clinical risk category for high dose interleukin-2 (HD IL-2) treated patients with metastatic renal cell cancer (mRCC): data from the PROCLAIM(SM) registry
por: Fishman, M., et al.
Publicado: (2019) -
Open-label, randomized, multi-center study comparing the sequence of high dose Aldesleukin (Proleukin(® )(HD IL-2) and Ipilimumab Yervoy(® )) in patients with metastatic melanoma (proclivity 02)
por: Patel, Sapna, et al.
Publicado: (2014) -
A multi-center study of high dose Aldesleukin (Proleukin(® )(HD IL-2) + Vemurafenib Zelboraf(® )) therapy in patients with BRAF(V600 )mutation positive metastatic melanoma (proclivity 01)
por: Clark, Joseph, et al.
Publicado: (2014) -
The Gospel of Hahnemann: How Are We Proclaiming It?
por: Kennedy, A. L.
Publicado: (1899)